Article
Article: mRNA: A New Option for Vaccines & Therapies
The use of mRNA for vaccines & therapeutics is being explored due to the advantages that the technology presents, and the promise of mRNA was demonstrated by COVID-19 vaccines, which provided a pathway for future therapeutics to employ this technology.
View Now
Article
Article: Streamlining Process Characterization Toward Successful Validation Campaigns
Understanding processes in the development and manufacture of biological drug substances is crucial to successfully navigating the clinical phases towards commercial launch, all within ever‑tightening time constraints, and regulatory frameworks.
View Now
Offering Fact Sheet
UpTempo℠ Antibody Platform Process
Summary: A single solution integrating development through complete clinical supply to simplify, accelerate and de-risk your monoclonal antibody (mAb) development.
View Now
Webinars
Webinar – Process Optimization for Monoclonal Antibody (mAb) Commercial Manufacturing
In this webinar, experts will discuss the evolution of protocols associated with induced pluripotent stem cell (iPSC) generation and differentiation.
View Now
Video
GPEx® Lightning: The Latest Cell Line Development Technology
Summary: Leveraging Catalent’s proven GPEx expression platform in a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line system, GPEx Lightning combines innovative technologies, including a novel gene insertion technology, to further shorten drug substance development by up to three months compared to previous timelines.
View Now
Video
Choosing a CDMO Partner for Your Late-Stage and Commercial Biologics Programs
Summary: Learn more on considerations for choosing the right CDMO for your late-stage biotherapeutics programs in this interview with Stacey Treichler, Ph.D., Director, Head of Marketing & Strategy, BioModalities, Catalent Biologics.
View Now
Video
The Unique Challenges of Lipid Nanoparticle Development and Manufacturing
Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 3 of 3 in the mRNA fireside chat series with Catalent’s experts).
View Now
Video
mRNA Development and Manufacturing - CMC challenges and Solutions
Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 2 of 3 in the mRNA fireside chat series with Catalent’s experts).
View Now
Video
mRNA: A New Option for Vaccines and Therapeutics
Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 1 of 3 in the mRNA fireside chat series with Catalent’s experts).
View Now
Webinars
Streamlining Process Characterization Toward Successful Validation Campaigns
Summary: In this webinar, we explore the drivers for process characterization and late-phase development including improving process understanding, enhancing robustness, and assurance that it delivers...
View Now
